Evaluation of a new Trypanosoma cruzi antibody assay for blood donor screening
- 7 December 2007
- journal article
- research article
- Published by Wiley in Transfusion
- Vol. 48 (3), 531-540
- https://doi.org/10.1111/j.1537-2995.2007.01566.x
Abstract
BACKGROUND: This multicenter prospective study was designed to evaluate the performance characteristics of a new commercially available enzyme‐linked immunosorbent assay (ELISA) for the detection of antibodies to Trypanosoma cruzi in blood donors, the ORTHO T. cruzi ELISA Test System (Ortho‐Clinical Diagnostics). STUDY DESIGN AND METHODS: Assay specificity was evaluated among 40,665 serum and ethylenediaminetetraacetate (EDTA) plasma specimens from volunteer blood donors and 481 T. cruzi antibody–negative specimens from a high‐risk population. Sensitivity was evaluated among 106 T. cruzi‐infected subjects identified by parasite detection, among 93 radioimmunoprecipitation assay (RIPA)‐positive specimens from high‐risk subjects, and 662 specimens presumed positive for the presence of T. cruzi antibodies by serologic methods. Also assessed were the equivalence of serum and plasma as specimen sources, performance equivalence of automated and semiautomated processing methods, nonspecific reactivity in specimens from other disease states or clinical conditions, and assay precision. RESULTS: Assay specificity was 99.998 percent in volunteer blood donors and 99.4 percent among high‐risk subjects. Sensitivity was 100 percent among specimens positive by parasite detection, or by serologic methods, and 98.9 percent among RIPA‐positive specimens from high‐risk subjects. No differences were demonstrated between serum and plasma or between semiautomated and automated processing methods. Cross‐reactivity was observed with known positive leishmaniasis specimens. Total inter‐ and intraassay variability was less than 10 percent with both the automated and the semiautomated methods. CONCLUSION: The ORTHO T. cruzi ELISA Test System is an effective, qualitative assay for screening blood donors for immunoglobulin G antibodies to T. cruzi. The assay was licensed for donor screening by the FDA in December 2006.Keywords
This publication has 32 references indexed in Scilit:
- Evaluation of a new enzyme-linked immunosorbent assay for detection of Chagas antibody in US blood donorsTransfusion, 2007
- Field evaluation of four novel enzyme immunoassays for Chagas' disease in Venezuela blood banks: comparison of assays using fixed-epimastigotes, fixed-trypomastigotes or trypomastigote excreted?secreted antigens from two Trypanosoma cruzi strainsTransfusion Medicine, 2006
- Serological diagnosis of Trypanosoma cruzi: evaluation of three enzyme immunoassays and an indirect immunofluorescent assayJournal of Medical Microbiology, 2006
- Purified Excreted-Secreted Antigens from Trypanosoma cruzi Trypomastigotes as Tools for Diagnosis of Chagas' DiseaseJournal of Clinical Microbiology, 2006
- Transfusion-associated Chagas disease (American trypanosomiasis) in Mexico: implications for transfusion medicine in the United StatesTransfusion, 2006
- The validity of serologic tests for Trypanosoma cruzi and the effectiveness of transfusional screening strategies in a hyperendemic regionTransfusion, 2005
- Chagas' disease: application of TESA-blot in inconclusive sera from a Brazilian blood bankVox Sanguinis, 2004
- Threats to blood safety posed by emerging protozoan pathogensVox Sanguinis, 2004
- Serodiagnosis of Chronic and Acute Chagas' Disease with Trypanosoma cruzi Recombinant Proteins: Results of a Collaborative Study in Six Latin American CountriesJournal of Clinical Microbiology, 2004
- Evaluation of the Performance of Brazilian Blood Banks in Testing for Chagas' DiseaseVox Sanguinis, 1998